Gilead Sciences
GILD
1,600 hedge funds and large institutions have $59.1B invested in Gilead Sciences in 2022 Q1 according to their latest regulatory filings, with 144 funds opening new positions, 699 increasing their positions, 561 reducing their positions, and 208 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 699 | Existing positions reduced: 561
12% more call options, than puts
Call options by funds: $1.38B | Put options by funds: $1.22B
4% more funds holding in top 10
Funds holding in top 10: 23 → 24 (+1)
1.5% less ownership
Funds ownership: 80.79% → 79.28% (-1.5%)
5% less funds holding
Funds holding: 1,682 → 1,600 (-82)
19% less capital invested
Capital invested by funds: $73.3B → $59.1B (-$14.2B)
31% less first-time investments, than exits
New positions opened: 144 | Existing positions closed: 208
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$880M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$436M |
| 3 |
Renaissance Technologies
New York
|
+$410M |
| 4 |
D.E. Shaw & Co
New York
|
+$285M |
| 5 |
Millennium Management
New York
|
+$232M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$3.27B |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$1.94B |
| 3 |
Amundi
Paris,
France
|
-$264M |
| 4 |
Barclays
London,
United Kingdom
|
-$156M |
| 5 |
Morgan Stanley
New York
|
-$136M |
GILD Hedge Fund Activity: Q1 2022 in Review
1,600 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q1 2022, worth a combined $59.1B — down 19% from $73.3B a quarter earlier.
Sellers outnumbered buyers: 208 funds closed out of GILD and 144 opened new positions — a net loss of 64 holders — while 561 trimmed existing stakes and 699 added.
The largest buyer was Arrowstreet Capital, adding an estimated $880M. The largest seller was Capital Research Global Investors, cutting an estimated $3.27B.
- 1,600 institutional investors held Gilead Sciences (GILD) as of Q1 2022, down from 1,682 in Q4 2021.
- Funds reported $59.1B of Gilead Sciences stock for Q1 2022, down 19% quarter-over-quarter.
- 144 funds opened new Gilead Sciences positions in Q1 2022 and 208 closed out, a net change of -64 holders.
- The largest Gilead Sciences buyer in Q1 2022 was Arrowstreet Capital, an estimated $880M added.
- The largest Gilead Sciences seller in Q1 2022 was Capital Research Global Investors, an estimated $3.27B sold.
Based on aggregated 13F filings for Q1 2022.